Clinical Trials

Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials

Chase Doyle

October 2019, Vol 10, No 5 - Clinical Trials

San Diego, CA—New research sponsored by the National Cancer Institute highlights the uphill battle faced by patients with limited financial resources even in clinical trials. According to data presented at the 2019 ASCO Quality Care Symposium, patients with Medicaid or with no insurance had significantly worse overall survival in positive clinical trials compared with privately insured patients. [ Read More ]

Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma

Wayne Kuznar

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO 2018 Highlights - Clinical Trials, Multiple Myeloma

Chicago, IL—The triplet regimen of pomalidomide (Pomalyst), bortezomib (Velcade), and low-dose dexamethasone (PVd) significantly extended progression-free survival (PFS) compared with the doublet of bortezomib plus dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma who had previously received lenalidomide [ Read More ]